107 related articles for article (PubMed ID: 26424413)
41. Regulation of the p53 tumor suppressor protein.
Oren M
J Biol Chem; 1999 Dec; 274(51):36031-4. PubMed ID: 10593882
[No Abstract] [Full Text] [Related]
42. Nothing to gain for p53.
Harjes U
Nat Rev Cancer; 2019 Oct; 19(10):544-545. PubMed ID: 31471582
[No Abstract] [Full Text] [Related]
43. Novel function of cytoplasmic p53 at the interface between mitochondria and the endoplasmic reticulum.
Kroemer G; Bravo-San Pedro JM; Galluzzi L
Cell Death Dis; 2015 Mar; 6(3):e1698. PubMed ID: 25789973
[No Abstract] [Full Text] [Related]
44. Taking up the reins of power: metabolic functions of p53.
Humpton T; Vousden KH
J Mol Cell Biol; 2019 Jul; 11(7):610-614. PubMed ID: 31282931
[No Abstract] [Full Text] [Related]
45. Genome-wide studies of the transcriptional regulation by p53.
Li M; He Y; Feng X; Huang J
Biochim Biophys Acta; 2012 Jul; 1819(7):684-7. PubMed ID: 22348878
[TBL] [Abstract][Full Text] [Related]
46. p53 mutants: the achilles' heel of human cancers?
Brachmann RK
Cell Cycle; 2004 Aug; 3(8):1030-4. PubMed ID: 15280671
[TBL] [Abstract][Full Text] [Related]
47. Polymorphism of p53 in cancer prognosis.
Pillai RM; Nair SA
Indian J Med Res; 2016 Sep; 144(3):314-316. PubMed ID: 28139528
[No Abstract] [Full Text] [Related]
48. Gene expression changes as potential biomarkers of tumour bearing status in humans.
Ember I; Kiss I; Faluhelyi Z
Eur J Cancer Prev; 1998 Aug; 7(4):347-8. PubMed ID: 9806124
[No Abstract] [Full Text] [Related]
49. Promotability and tissue specificity of hereditary cancer genes: do hereditary cancer patients have a reduced requirement for tumor promotion because all their somatic cells are heterozygous at the predisposing locus?
Paraskeva C; Williams AC
Mol Carcinog; 1992; 5(1):4-8. PubMed ID: 1543540
[No Abstract] [Full Text] [Related]
50. Arsenic and an Old Place: Rescuing p53 Mutants in Cancer.
Loh SN
Cancer Cell; 2021 Feb; 39(2):140-142. PubMed ID: 33561393
[TBL] [Abstract][Full Text] [Related]
51. Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants.
Danziger SA; Zeng J; Wang Y; Brachmann RK; Lathrop RH
Bioinformatics; 2007 Jul; 23(13):i104-14. PubMed ID: 17646286
[TBL] [Abstract][Full Text] [Related]
52. Cancer as a Genetic or Epigenetic Disease?
Ribatti D
Crit Rev Eukaryot Gene Expr; 2021; 31(5):1-5. PubMed ID: 34591384
[TBL] [Abstract][Full Text] [Related]
53. P53 clears aneuploid cells by entosis.
Rizzotto D; Villunger A
Cell Death Differ; 2021 Feb; 28(2):818-820. PubMed ID: 33149274
[No Abstract] [Full Text] [Related]
54. Cancer and epigenetic reversion--the fundamental role of redox.
Papadopulos-Eleopulos E; Page BA; Causer D; Turner VF; Papadimitriou JM
Am J Pathol; 2007 Nov; 171(5):1726-7; author reply 1727. PubMed ID: 17982134
[No Abstract] [Full Text] [Related]
55. Genetic and cellular mechanisms of oncogenesis.
Marshall C; Vousden K
Curr Opin Genet Dev; 2011 Feb; 21(1):1-3. PubMed ID: 21273056
[No Abstract] [Full Text] [Related]
56. A year of change for Journal of Molecular Cell Biology.
J Mol Cell Biol; 2020 Jan; 12(1):1. PubMed ID: 32064527
[No Abstract] [Full Text] [Related]
57. Summary of the International Cancer Microenvironment from meeting in Pittsburgh, Pennsylvania on October 3-6, 1999.
Herberman RB; Whiteside TL
Cancer Res; 2000 Mar; 60(5):1465-9. PubMed ID: 10728715
[No Abstract] [Full Text] [Related]
58. Beyond cancer genomics: after the end of the beginning.
Venkitaraman AR
Curr Opin Genet Dev; 2012 Feb; 22(1):1-2. PubMed ID: 22402446
[No Abstract] [Full Text] [Related]
59. Impact of genetic targets on cancer therapy. Forward.
El-Deiry WS
Adv Exp Med Biol; 2013; 779():v-vi. PubMed ID: 23461003
[No Abstract] [Full Text] [Related]
60. Q&A: Gordon Mills on Neomorphs in Cancer.
Cancer Discov; 2016 Oct; 6(10):1076. PubMed ID: 27609219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
